Somatic mutations and germline sequence variants in the expressed tyrosine kinase genes of patients with de novo acute myeloid leukemia.
about
FES kinases are required for oncogenic FLT3 signalingDNA sequencing of a cytogenetically normal acute myeloid leukaemia genomeGenetic characterization of TET1, TET2, and TET3 alterations in myeloid malignanciesDiscovery of a Potent and Selective DDR1 Receptor Tyrosine Kinase InhibitorNTRK gene fusions as novel targets of cancer therapy across multiple tumour typesTRKing down an old oncogene in a new era of targeted therapyGemcitabine and arabinosylcytosin pharmacogenomics: genome-wide association and drug response biomarkersThe origin and evolution of mutations in acute myeloid leukemiaIntegrated genomic analysis implicates haploinsufficiency of multiple chromosome 5q31.2 genes in de novo myelodysplastic syndromes pathogenesis.Analysis of AML genes in dysregulated molecular networksSequence and structure signatures of cancer mutation hotspots in protein kinasesc.1810C>T polymorphism of NTRK1 gene is associated with reduced survival in neuroblastoma patients.Proteomic and genetic approaches identify Syk as an AML target.What are the endpoints of therapy for acute leukemias? Old definitions and new challenges.Ras oncogene-independent activation of RALB signaling is a targetable mechanism of escape from NRAS(V12) oncogene addiction in acute myeloid leukemia.Recurrent expression signatures of cytokines and chemokines are present and are independently prognostic in acute myelogenous leukemia and myelodysplasiaAssociation of a leukemic stem cell gene expression signature with clinical outcomes in acute myeloid leukemia.Mcl1 haploinsufficiency protects mice from Myc-induced acute myeloid leukemia.Spectral clustering using Nyström approximation for the accurate identification of cancer molecular subtypesCancer driver mutations in protein kinase genesIbrutinib inhibits SDF1/CXCR4 mediated migration in AMLMutated genes, pathways and processes in tumours.Kinase pathway dependence in primary human leukemias determined by rapid inhibitor screening.Dasatinib inhibits the growth of molecularly heterogeneous myeloid leukemias.Rapid Identification of Therapeutic Targets in Hematologic Malignancies via Functional Genomics.PML-RARA can increase hematopoietic self-renewal without causing a myeloproliferative disease in mice.Sequencing a mouse acute promyelocytic leukemia genome reveals genetic events relevant for disease progressionDDR1 receptor tyrosine kinase promotes prosurvival pathway through Notch1 activation.Integrated differential transcriptome maps of Acute Megakaryoblastic Leukemia (AMKL) in children with or without Down Syndrome (DS)Sparse expression bases in cancer reveal tumor drivers.Integrative analysis of type-I and type-II aberrations underscores the genetic heterogeneity of pediatric acute myeloid leukemiaOur changing view of the genomic landscape of cancer.PU.1 is essential for MLL leukemia partially via crosstalk with the MEIS/HOX pathway.Epigenomic analysis of the HOX gene loci reveals mechanisms that may control canonical expression patterns in AML and normal hematopoietic cells.Rara haploinsufficiency modestly influences the phenotype of acute promyelocytic leukemia in mice.Discoidin domain receptor tyrosine kinases: new players in cancer progressionMutational heterogeneity in human cancers: origin and consequences.The significance of low PU.1 expression in patients with acute promyelocytic leukemia.Overexpression of IL-1 receptor accessory protein in stem and progenitor cells and outcome correlation in AML and MDS.Resequencing analysis of the candidate tyrosine kinase and RAS pathway gene families in multiple myeloma.
P2860
Q24297863-8791113F-1D2D-4DCB-AE9E-F93FBD43A8F8Q24644436-1432B9A4-D73D-4719-8824-41110FB489C1Q24648438-7D9E3BB6-4025-4B07-B303-52BBB66E1616Q27679284-28276D99-317F-475B-A8FC-0364A124FBDDQ28066821-2C8D020C-1ECA-4A6B-8D90-72785B38A88DQ28254287-CC22A77B-1956-4CF2-9866-6F09EA0B9E54Q28471821-2155B4C1-34EA-47CD-9AA1-80624339A36DQ29614630-54928760-DBEE-4865-9350-3FB003F29C24Q33412120-A0EDDAA3-FDED-41F6-BB83-4D92FFCBD331Q33504376-28BC7C58-4258-4396-AC54-6B1FE24772C8Q33510934-82B24838-F594-4F55-BFE3-0EB1ECBD07D9Q33517966-7719B53D-AD60-49CA-9474-7FACD050A4F7Q33577098-14ED61AC-1A60-44BF-8034-9B9E66AB9E80Q33775647-806E460D-81A3-4B65-AD3E-0CEFB250D14FQ33779805-149FD9E1-1597-4239-AA4F-F458466549FEQ33843736-B00AC589-13B3-4BF1-99C7-650E13F0D047Q33873844-AF176475-47B7-4902-BD74-EB5692475ECBQ33882849-C7A12778-69B8-4D2A-85D3-7E2CF52E62A8Q33884798-B125E652-E899-42FC-B2A3-33B375E80286Q34002709-7E26B202-DFC1-4D8E-BCA5-15CB61D3B2FFQ34042250-7ADF0B13-BDB0-4479-A3C2-4E3723B61D17Q34166906-3130DFB0-4FF5-4896-9D3A-9516C586AAEBQ34307423-D76E956D-BC11-44CB-BDE6-9962AB4FCCC6Q34335004-9DBCD654-3DF4-46B1-ABF1-27214894F6C7Q34654334-53B62478-D2AE-43EA-B332-D54D209DE1BBQ34749039-17F7988E-1D43-44BF-81DC-2F3AC436D3F1Q34755408-A89829A6-F93D-48FE-BCE5-B192C86F3E88Q34978948-333DFDEE-34E2-434C-A7CB-ABC9D3337E68Q35005153-EADC891A-58E8-4754-8299-48738F336AB4Q35088941-E7CBE53B-5B11-45C1-BEB6-E3D667B3AB01Q35265916-D654E800-03D1-4E48-BBD8-DDA5779E6802Q35368205-1D365287-0211-47EB-A94C-93AE9EAFDC32Q35541213-731DA004-A4CE-4D93-9BB1-19EA16400D01Q35685082-06779A2A-CA4A-43FC-9694-FF0A70C00BDDQ35866178-00E58386-F5ED-4D3F-87A7-27B3450437FCQ35957518-9B5DB39D-2922-44B9-8DC7-250F8107DB07Q36031579-5BAF84E5-4CBA-4649-B691-22ECE9B697ABQ36125630-01C36EC1-D4F7-49D1-8331-56742946968BQ36163066-2FB8DBD1-2C44-4E34-AFD2-D8DE6CDD9683Q36234936-91B43831-B83E-41DD-A81B-DF2F2418436F
P2860
Somatic mutations and germline sequence variants in the expressed tyrosine kinase genes of patients with de novo acute myeloid leukemia.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
2008年论文
@zh
2008年论文
@zh-cn
name
Somatic mutations and germline ...... e novo acute myeloid leukemia.
@ast
Somatic mutations and germline ...... e novo acute myeloid leukemia.
@en
type
label
Somatic mutations and germline ...... e novo acute myeloid leukemia.
@ast
Somatic mutations and germline ...... e novo acute myeloid leukemia.
@en
prefLabel
Somatic mutations and germline ...... e novo acute myeloid leukemia.
@ast
Somatic mutations and germline ...... e novo acute myeloid leukemia.
@en
P2093
P2860
P1433
P1476
Somatic mutations and germline ...... e novo acute myeloid leukemia.
@en
P2093
Daniel C Link
Daved H Fremont
Elaine R Mardis
Jacqueline E Payton
John F DiPersio
Mark Watson
Matthew J Walter
Michael D McLellan
Michael H Tomasson
P2860
P304
P356
10.1182/BLOOD-2007-09-113027
P407
P577
2008-02-12T00:00:00Z